antisense compound

AVI BioPharma begins testing intravenous delivery of its experimental compound for DMD

posted on March 3, 2009 - 10:00pm
AVI BioPharma of Portland, Ore., has started the systemic (through the blood) delivery phase of its clinical trial of AVI4658 in Duchenne muscular dystrophy (DMD). The trial is being conducted in the United Kingdom.

New content is being added every day. Please check back again.